Effects of adalimumab on health-related quality of life in psoriasis patients with and without comorbid psoriatic arthritis: Value of reducing PASI scores and systemic inflammation - 21/04/16
Martin Okun, Fort HealthCare, Dallas, TX, United States; Min Yang, Analysis Group, Inc, Boston, MA, United States; Valerie Koo, Analysis Group, Inc, Boston, MA, United States; Murali Sundaram, AbbVie Inc, North Chicago, IL, United States; James Signorovitch, Analysis Group, Inc, Boston, MA, United States
Le texte complet de cet article est disponible en PDF. Design, study conduct, and financial support for the study were provided by AbbVie; AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication. |
Vol 74 - N° 5S1
P. AB246 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?